{
    "nctId": "NCT03648983",
    "briefTitle": "Arm Circumference Measurement With or Without Bioimpedance Spectroscopy in Finding Lymphedema Early in Patients With Stage I-III Breast Cancer",
    "officialTitle": "A Pilot Randomized Trial Comparing Arm Circumference and Bioimpedance Measurement for Early Detection and Treatment of Lymphedema in Patients Undergoing Axillary Lymph Node Dissection or Sentinel Node Biopsy",
    "overallStatus": "TERMINATED",
    "conditions": "Lymphedema, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 95,
    "primaryOutcomeMeasure": "Rates of Enhanced Lymphedema Detection",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Newly diagnosed with stage I-III cancer of the female breast\n* Patients scheduled to receive any type of radiation therapy to the breast or axilla are eligible; however, they must be registered to this study with pre-surgery measures taken prior to receiving neoadjuvant therapy as well as before surgery\n* Patients scheduled to receive neoadjuvant chemotherapy are also eligible; however, they must be registered to this study with pre-surgery measurements taken prior to receiving neoadjuvant therapy as well as before surgery\n* Patients with a history of other invasive malignancies are eligible as long as they have no evidence of disease 5 years post-diagnosis\n* Patients with basal cell and squamous cell cancer of the skin are eligible\n* Patients willing to return to the study site for the duration of the study (34 months)\n\nExclusion Criteria:\n\n* Pregnant women\n* Patients who are homebound or dependent upon a walker or wheelchair for mobility\n* Patients diagnosed enhanced lymphedema\n* Hypertensive patients who are using diuretics\n* Documented cardiac conduction disturbances, unstable angina, dementia, or any other chronic disease which, in the opinion of the treating physician, significantly increases mortality over the next 2 years\n* Prior history of carcinoma in situ, lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), or invasive breast cancer",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}